HDAC3 and acute myeloid leukemia: Inhibition of HDAC3, a facilitator of AKT phosphorylation, significantly impeded AML progression and enhanced the susceptibility of MLL-AF9-positive AML cells to chemotherapy (Long et al., 2017).